SBI Healthcare Opp Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
- September 10, 2026
- Posted by: Chaitanya Auti
- Category: Mutual Funds
SBI Healthcare Opp Fund Direct Growth Plan currently has a NAV of ₹608.2842 as of 09 Sep 2026 and scheme AUM of ₹5,796 Cr. Its 1-year, 3-year and 5-year returns are 22.46%, 24.61% and 18.76%, respectively, and it sits in the High Risk category.
Our view is that this is a focused healthcare fund with strong long-term compounding and a clear sector tilt. The return profile has been better than the benchmark over every tracked period, but the portfolio concentration means investors need to be comfortable with sharper swings than a diversified equity fund.
Quick facts
| Particular | Details |
|---|---|
| NAV | ₹608.2842 as of 09 Sep 2026 |
| AUM | ₹5,796 Cr |
| Expense Ratio | 0.91% |
| Launch Date | 01 Jan 2013 |
| Min SIP | ₹500 |
| Risk Category | High Risk |
| Benchmark | Nifty 50 |
| Fund Category | Equity |
| Exit Load | 0.50% on or before 15D, Nil after 15D |
| Fund Managers | Tanmaya Desai |
The fund is managed by Tanmaya Desai.
Source data date: as of 09 Sep 2026
Performance
| Period | Fund return | Benchmark return |
|---|---|---|
| 1M | 0.68% | -4.69% |
| 3M | 12.46% | 0.93% |
| 1Y | 22.46% | -7.16% |
| 3Y | 24.61% | 6% |
| 5Y | 18.76% | 5.87% |
The fund has been firm in the most recent stretch, with a positive 1-month result and a much stronger 3-month outcome than the benchmark. That matters because the benchmark has been weak over the same recent periods, so the fund’s relative edge is not just a long-horizon story.
The longer record is also healthy. The 3-year return of 24.61% and the 5-year return of 18.76% both sit well ahead of the benchmark’s 6% and 5.87%, which points to stronger compounding over time rather than a one-off jump.
The path has not been perfectly smooth, though. The one-year pattern shows periods of pressure before a recovery, which is consistent with a sector-focused equity strategy that can move differently from the broad market. Even so, the direction of travel over 3 years and 5 years remains constructive.
For an investor, the key read-through is that this fund has outpaced the benchmark across short, medium and longer horizons, but it does so inside a high-risk framework. That combination can suit someone who is willing to accept volatility in exchange for sector-led upside.
Source data date: as of 09 Sep 2026
Should you BUY or HOLD SBI Healthcare Opp?
A fund’s past returns alone don’t tell you whether you should buy it today or continue holding it.
The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.
Already holding SBI Healthcare Opp? Thinking of investing now?
Peer comparison
| Fund | 1Y return | 3Y return | 5Y return |
|---|---|---|---|
| SBI Healthcare Opp Fund Direct Growth Plan | 22.46% | 24.61% | 18.76% |
| ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan | 71.49% | 36.55% | Data not available |
| Motilal Oswal Active Momentum Fund Direct Growth Plan | 30.08% | Data not available | Data not available |
| Kotak Healthcare Fund Direct Growth Plan | 28.85% | Data not available | Data not available |
| HDFC Pharma and Healthcare Fund Direct Growth Plan | 28.6% | Data not available | Data not available |
| PGIM India Healthcare Fund Direct Growth Plan | 27.47% | Data not available | Data not available |
This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. On 1-year returns, the fund trails the strongest peer figure in this set, but it stays close to the cluster of healthcare-oriented peers and remains ahead of the benchmark. The longer-term comparison is more limited because most peers do not have 3-year and 5-year figures available, yet the available numbers still show the fund holding up well on a medium-term basis.
That makes the picture mixed but useful. The short-term peer view suggests there are peers with stronger recent momentum, while the available 3-year history shows this fund has built a steadier compounding base than the benchmark. Investors comparing only these figures may see a fund that is not the most explosive on recent returns, but still shows credible longer-horizon delivery.
Source data date: as of 09 Sep 2026
Want to know more? Log in to Univest for more mutual fund insights.
Portfolio: where your money goes
| Holding | Sector | Weight |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 12.33% |
| Divi’S Laboratories Ltd. | Healthcare | 8.17% |
| Acutaas Chemicals Ltd. | Healthcare | 4.91% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 4.91% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.72% |
| Cipla Ltd. | Healthcare | 4.67% |
| Max Healthcare Institute Ltd. | Healthcare | 4.31% |
| TREPS | Cash & Cash Equivalents and Net Assets | 4.11% |
| Laurus Labs Ltd. | Healthcare | 3.96% |
| Aurobindo Pharma Ltd. | Healthcare | 3.9% |
The largest holding, Sun Pharmaceutical Industries Ltd., carries a weight of 12.33%, so it is likely to have a noticeable influence on how the fund behaves. After that, the weights step down fairly quickly, with the tenth holding at 3.9%, which shows that the portfolio is not built around one dominant position alone.
The top 10 holdings account for approximately 55.99% of the portfolio. That leaves a meaningful remainder across the other disclosed positions, so the fund appears concentrated enough for stock-specific outcomes to matter, but not so concentrated that one holding alone defines the result.
With 31 holdings disclosed, the portfolio has a visible tail beyond the top names. In practice, that mix may allow the healthcare theme to stay central while still spreading some risk across several companies and a small cash-equivalent allocation.
To see all holdings, visit the SBI Healthcare Opp Fund Direct Growth Plan page
Source data date: as of 09 Sep 2026
Who should invest
This fund may suit investors who are comfortable with High Risk exposure and can stay invested for a longer horizon. The return pattern shows strong 1-year, 3-year and 5-year numbers, while the benchmark has lagged over the same windows, which supports a case for patient investors who understand sector cycles.
The main trade-off is clear: you get the chance to participate in healthcare-led upside, but you also accept a sharper ride than a broad-market equity fund. The portfolio is tilted heavily toward healthcare names, so investors should be ready for theme-specific movements and not expect it to behave like a diversified index fund.
Tax and exit load
| Holding period | Tax rate | Description |
|---|---|---|
| Units held less than 1 year | 20% | Short-term capital gains tax |
| Units held more than 1 year | 12.5% | Long-term capital gains tax |
Exit load: 0.50% if units are sold on or before 15 days; nil after 15 days.
Source data date: as of 09 Sep 2026
Frequently asked questions
What is the current NAV of SBI Healthcare Opp Fund Direct Growth Plan?
The current NAV is ₹608.2842 as of 09 Sep 2026.
How has the fund performed over 1 year, 3 years and 5 years?
Its 1-year return is 22.46%, its 3-year return is 24.61% and its 5-year return is 18.76%.
How does the fund compare with the benchmark?
It has outperformed the benchmark across 1 month, 3 months, 1 year, 3 years and 5 years. The benchmark returns are -4.69%, 0.93%, -7.16%, 6% and 5.87% for those periods.
How does it compare with the peer funds listed here?
On the available 1-year figures, some peers have higher recent returns, including ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan at 71.49%. The fund still compares well on longer-horizon figures where available, especially against the benchmark.
Is there a minimum SIP amount?
The fund allows SIPs, but a minimum SIP amount is not stated in the available details.
Who manages the fund and what is the exit load?
The fund is managed by Tanmaya Desai. The exit load is 0.50% if units are sold on or before 15 days, and nil after 15 days.
Bottom line
SBI Healthcare Opp Fund Direct Growth Plan has shown a stronger long-term return profile than the benchmark, and its recent numbers have also stayed positive. The peer view is more mixed on 1-year performance, but the fund still presents a coherent medium- to long-term compounding record. Its High Risk label and healthcare-heavy portfolio mean it is not a smooth ride, yet that same focus may appeal to investors who want a concentrated sector fund rather than a broad market holding.
Published on 10 September 2026 at 1:33 PM IST
Explore mutual funds with Univest
Review mutual fund data, compare performance and explore fund insights on Univest.
RIA disclosure
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.